"If I'm better than average, then I'm ok?": Comparative information influences beliefs about risk and benefits
"If I'm better than average, then I'm ok?": Comparative information influences beliefs about risk and benefits
复制标题
DOI：
10.1016/j.pec.2007.08.008
复制
发表时间：
2007-12-01
影响因子：
3.5
通讯作者：
Ubel, Peter A.
中科院分区：
文献类型：
--
作者：
Fagerlin, Angela;Zikmund-Fisher, Brian J.;Ubel, Peter A.
目的：为了测试是否提供比较风险信息的变化risk perceives.Methods：249名女性游客到医院食堂被随机分为两个不同的条件之一，无论他们假设的乳腺癌的风险是低于或高于平均妇女的。参与者阅读一个描述乳腺癌预防药丸的场景，并指出他们：（1）服用药丸的可能性和（2）对药丸是否能降低乳腺癌风险的看法。被告知她们患乳腺癌的假设风险高于平均水平的女性更有可能支持服用避孕药（2.79vs.2.23，F = 4.95，p = 0.002），并且更可能相信避孕药能显著降低乳腺癌的风险（3.15vs.2.73，F = 4.32，p 0.005），即使风险是相等的。结论：向人们提供比较风险信息会改变他们的风险认知。高于平均水平的风险的人可能会觉得被迫采取治疗，因为他们是在平均水平以上的风险，因此可能不会彻底考虑权衡的风险和好处treatment.Practice影响：医生和决策援助开发人员必须重新考虑的做法，沟通“平均风险”的信息给患者。出版社：Elsevier爱尔兰Ltd.
Objective: To test whether providing comparative risk information changes risk perceptions.Methods: Two hundred and forty-nine female visitors to a hospital cafeteria were randomized to one of two conditions which differed in whether their hypothetical breast cancer risks was lower or higher than the average women's. Participants read a scenario describing a breast cancer prevention pill and indicated their: (1) likelihood of taking the pill and (2) perception of whether the pill provides breast cancer risk reduction.Results: Women told that their hypothetical risk of breast cancer was above average were more likely to endorse taking the pill (2.79 vs. 2.23, F 4.95, p = 0.002) and more likely to believe that the pill provided a significant risk reduction in breast cancer (3.15 vs. 2.73, F = 4.32, p 0.005), even though the risks were equivalent.Conclusions: Providing people with comparative risk information changes their risk perceptions. People who have above average risk may feel compelled to take a treatment because they are at above average risk and therefore may not thoroughly consider the trade-offs in the risks and benefits of treatment.Practice implications: Physicians and decision aid developers must reconsider the practice of communicating "average risk" information to patients. Published by Elsevier Ireland Ltd.